TABLE 3.

Investigator and patient satisfaction with treatment

	Baseline (with ICS treatment only)				Week 8 (with add-on montelukast)
	Low-dose ICS	Moderate-dose ICS	High-dose ICS	Total	Low-dose ICS	Moderate-dose ICS	High-dose ICS	Total	P*
Patient global satisfaction with treatment, n (%)
Very satisfied	2 (1.5)	7 (4.4)	0 (0.0)	9 (2.8)	50 (38.8)	58 (42.6)	6 (26.1)	114 (39.6)	<0.001
Satisfied	12 (9.0)	10 (6.3)	3 (12.0)	25 (7.9)	50 (38.8)	43 (31.6)	13 (56.5)	106 (36.8)
Neither satisfied nor dissatisfied	52 (38.8)	65 (40.9)	5 (20.0)	122 (38.4)	22 (17.1)	19 (14.0)	2 (8.7)	43 (14.9)
Dissatisfied	64 (47.8)	67 (42.1)	13 (52.0)	144 (45.3)	4 (3.1)	16 (11.8)	1 (4.3)	21 (7.3)
Very dissatisfied	4 (3.0)	9 (5.7)	3 (12.0)	16 (5.0)	3 (2.3)	0 (0.0)	1 (4.3)	4 (1.4)
Missing	0 (0.0)	1 (0.6)	1 (4.0)	2 (0.6)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Total	134	159	25	318	129	136	23	288
Investigator global satisfaction with treatment, n (%)
Very satisfied	3 (2.1)	6 (3.8)	0 (0.0)	9 (2.8)	46 (35.7)	51 (37.5)	10 (43.5)	107 (37.2)	<0.001
Satisfied	2 (1.5)	11 (6.9)	0 (0.0)	13 (4.1)	55 (42.6)	52 (38.2)	9 (39.1)	116 (40.3)
Neither satisfied nor dissatisfied	56 (41.8)	49 (30.8)	4 (16.0)	109 (34.3)	22 (17.1)	24 (17.6)	2 (8.7)	48 (16.7)
Dissatisfied	71 (53.0)	87 (54.7)	17 (68.0)	175 (55.0)	5 (3.9)	9 (6.6)	1 (4.3)	15 (5.2)
Very dissatisfied	2 (1.5)	6 (3.8)	4 (16.0)	12 (3.8)	0 (0.0)	0 (0.0)	1 (4.3)	1 (0.3)
Missing	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (0.8)	0 (0.0)	0 (0.0)	1 (0.3)

^*Based on McNemar-Bowker Test for total. P values for dose stratification could not be computed due to small sample. ICS Inhaled corticosteroid